Testing TML-6 for Early Alzheimer's Disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new drug called TML-6 in people with early signs of Alzheimer's disease (either mild cognitive impairment or mild dementia). The goal is to see if TML-6 is safe and helps slow memory and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60–85 years old and either male or post-menopausal female (no period for 12+ months)
- You have a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease, confirmed by blood biomarkers and cognitive testing
- Your memory or thinking skills have been slowly declining for at least 6 months
- You have a study partner (family member or friend) who can spend at least 10 hours per week with you and help track your progress
- You have not received anti-amyloid therapy for Alzheimer's disease
- Your liver, kidney, and blood cell counts are within safe ranges, and you are not positive for HIV or hepatitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
This trial tests whether transcranial magnetic stimulation (TMS), a noninvasive brain treatment, can help people with early Alzheimer's or mild cognitive impairment. It aims to see if the treatment is safe and effective for slowing memory decline.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.